NFE2L2 and chronic kidney disease: Nrf2 activators were reported to be protective against oxalate-induced nephrolithiasis (Zhu et al., 2019), endothelial dysfunction in CKD (Aminzadeh et al., 2013), and ischemia–reperfusion injury (Liu et al., 2014).